Literature DB >> 17506513

Transient acid exposure increases sevelamer HCl phosphate binding.

Edward A Ross1, William E Scott, Anika A Odukale, Nicolas A Alba, Christopher D Batich.   

Abstract

The patient-to-patient variability in the dosing of sevelamer HCl for phosphate control led us to test whether the binder's transient exposure to acidic environments (such as the stomach) might alter the compound so as to change its subsequent binding capacity in the more alkaline small intestine. We hypothesized that an acid milieu could either increase the reactive sites (protonated amine groups) or make the polymer more hydrophilic (hydration and swelling allowing more phosphate to reach those sites). Eight hundred milligrams of Renagel tablets were exposed to pHs 1, 2.3, and 7 (n = 7 each acidity level) for 1 h. NaCl was added to keep ionic strength the same. Measured by atomic emission phosphate uptake after 3 h at pH 7 was, respectively, 3.13 +/- 0.21, 2.72 +/- 0.35, and 1.85 +/- 0.46 mequiv./g (p = 0.0006, pH 1 vs. pH 7). Semi-automated computerized image analysis was then performed to measure swelling of the particles. We constructed a glass continuous-flow cell that allowed stationary particles and real-time photography. Using digitized optical measurements there was no difference (p > 0.8) between the swelling after 1 h of pH 1 or 7 solutions (60.2 +/- 14.8% vs. 59.5 +/- 9.8% increase in diameter). Our findings support the importance of transient acid exposure in enhancing phosphate binding, due to increased protonated sites rather than by more swelling. Patients with acquired or pharmacologic achlorhydria would not benefit from this unexpected in vivo reaction. Possibly manufacturing sevelamer with a higher degree of protonation or administering it with appropriately acidic vehicles or beverages remains to be investigated. (c) 2007 Wiley-Liss, Inc. and the American Pharmacists Association.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17506513     DOI: 10.1002/jps.20914

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  1 in total

1.  Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients.

Authors:  Hitoshi Minakuchi; Tadashi Yoshida; Noriko Kaburagi; Teppei Fujino; Sho Endo; Tomoko Yamashita Takemitsu; Norimasa Yamashita; Hiroshi Itoh; Mototsugu Oya
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.